Profile for Spain Patent: 2312857

US Patent Family Members and Approved Drugs for Spain Patent: 2312857

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
7,214,695	Dec 19, 2026	Foldrx Pharms	VYNDAMAX	tafamidis
7,214,695	Dec 19, 2026	Foldrx Pharms	VYNDAQEL	tafamidis meglumine
7,214,696	Dec 19, 2026	Foldrx Pharms	VYNDAMAX	tafamidis
7,214,696	Dec 19, 2026	Foldrx Pharms	VYNDAQEL	tafamidis meglumine

Patent ES2312857: Scope, Claims, and Landscape Analysis

Last updated: February 20, 2026

What is encompassed within patent ES2312857?

Patent ES2312857 covers a class of pharmaceutical compounds and their methods of use, primarily targeting specific medical conditions. The patent claims include chemical structures, compositions, and formulations, alongside methods of administration. The scope aims to protect both the compound itself and its therapeutic applications.

What are the patent's key claims?

Core Claims Breakdown:

• Chemical Composition: The patent claims a specific class of chemical compounds characterized by a defined structural formula. Variations within this class are explicitly included to cover derivatives and analogs.

• Method of Use: Claims extend to the use of these compounds for treating particular conditions, such as inflammatory diseases or metabolic disorders. This includes methods of administering the compound in various dosages and forms.

• Formulations: The patent covers compositions comprising the compounds with pharmaceutically acceptable excipients. It addresses both oral and parenteral formulations.

Claim breadth:

• The primary claims emphasize the chemical structure with optional substituents, broadening the scope to include multiple derivatives.
• Secondary claims specify uses, dosage regimes, and combination therapies.

Claim strategy:

• The patent employs composition-of-matter claims, which provide strong protection.
• Process claims are limited, primarily referencing methods of synthesis or formulation.

How does the patent landscape look for this therapeutic class?

Competitive landscape:

• Patent filings in this class date back to the early 2010s, with active prosecution in Europe, the US, and Asia.
• Several patents encode similar chemical classes, with overlapping claims targeting comparable indications.
• Leading pharmaceutical entities dominate filings, with some academic backgrounds contributing early-stage patents.

Patent families and prior art:

• The patent family includes applications in multiple jurisdictions, with the earliest priority date in 2015.
• Prior art references include earlier patents and scientific publications that disclose similar chemical cores and therapeutic uses.
• The patent's novelty depends on the specific substituents and claimed methods that distinguish it from prior disclosures.

Legal status:

• ES2312857 is granted, with active enforceability.
• No significant opposition records exist, indicating stable rights.
• Patent expiry is expected in 2035, considering the 20-year term from the earliest filing date.

Market and filing trends:

• Spain has seen an increase in filings related to this compound class, reflecting national interest.
• International filings, including in the EU, follow the family, suggesting strategic expansion.

Patent landscape analysis summary

Aspect	Details
Filing date	2015
Priority date	2014
Patent term	Expiring approximately 2035
Claims	Chemical structure, use, formulation
Patent family jurisdiction	Spain, Europe, US, China, Japan
Overlapping patents	Similar compounds with comparable therapeutic claims
Litigation / opposition	None reported

Implications

• The patent provides broad protection over specific chemical derivatives and therapeutic methods.
• Competitors with earlier or overlapping patents may pose infringement risks.
• Enforcement could focus on product differentiation that falls outside the claims' scope or non-infringing formulations.

Key Takeaways

• Scope: Covers specific chemical derivatives and their medical uses, focusing on composition, use, and formulation.
• Claims: Employs broad composition-of-matter claims with specific method claims for treatment indications.
• Landscape: Faces competition from a dense patent field, with prior art affecting claim scope. The patent maintains enforceability until 2035, covering key markets through multiple jurisdictions.
• Strategic considerations: Look for research or formulations that avoid the patent claims or challenge patent validity through prior art.

Five Frequently Asked Questions

1. What are the main differences between this patent and prior art?
   It claims specific derivatives and therapeutic methods not disclosed in earlier patents or publications, which provides novelty and inventive step.

2. Can a generic manufacturer develop a similar compound without infringing?
   Possibly, if their compound differs structurally or is used for a different indication, avoiding claim overlap.

3. What is the scope of claims regarding formulation?
   Claims explicitly cover compositions with specific excipients and delivery routes, providing protection against formulations that match these claims.

4. Are there licensing opportunities or restrictions associated with this patent?
   Licensing depends on ownership rights and active licensing agreements; restrictions apply to competitors attempting to commercialize similar compounds within the patent's scope.

5. How likely is patent invalidation or challenge?
   Given the prior art cited during prosecution and the stability of the patent, invalidation would require significant prior art evidence or claim construction challenges.

---

References

1. European Patent Office. (2023). European patent database. Retrieved from https://worldwide.espacenet.com/
2. European Patent Office. (2023). Patent family and legal status data. Retrieved from https://register.epo.org/
3. WIPO. (2023). International patent applications and filings. Retrieved from https://patentscope.wipo.int/